A Novel Tyrosine Kinase Inhibitor Poised to Transform Advanced Lung Cancer Care Boehringer Ingelheim | Ridgefield, Conn., and Ingelheim, Germany…
Browsing: #FDAApproval
On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza, the first subcutaneous (SC) formulation of…
On August 15, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (IMFINZI®, AstraZeneca) in combination with platinum-containing chemotherapy…
IntroductionOn August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel (TECELRA) for treating adults with unresectable or metastatic…
On August 1, 2024, the U.S. Food and Drug Administration (FDA) approved an expanded indication for dostarlimab-gxly (Jemperli), in combination…